An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation

International Journal of Legal Medicine

Volumn 124, Issue 3, 2010, Pages 187-194

  Oechsler, Stephanie ^a   Skopp, Gisela ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Buprenorphine; Glucuronidation; Inhibition; Norbuprenorphine

Indexed keywords

AMITRIPTYLINE; BUPRENORPHINE; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; LAMOTRIGINE; NARCOTIC AGENT; NORBUPRENORPHINE; NORTRIPTYLINE; OXAZEPAM; TEMAZEPAM; TRIAZINE DERIVATIVE;

ARTICLE; HUMAN; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER; LIVER MICROSOME; MASS SPECTROMETRY; METABOLISM;

AMITRIPTYLINE; BUPRENORPHINE; CENTRAL NERVOUS SYSTEM AGENTS; CHROMATOGRAPHY, LIQUID; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MASS SPECTROMETRY; MICROSOMES, LIVER; NARCOTICS; NORTRIPTYLINE; OXAZEPAM; TEMAZEPAM; TRIAZINES;

EID: 77954564222     PISSN: 09379827     EISSN: 14371596     Source Type: Journal    
DOI: 10.1007/s00414-010-0418-8     Document Type: Article

References (27)

1. Lufty K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395-402
2. Elkader A, Sproule B (2005) Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 44:661-680
3. Huang W, Moody DE, McCance-Katz EF (2006) The in vivo glucuronidation of buprenorphine and norbuprenorphine deter-mined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther Drug Monit 28:245-251
4. Drogen - und Suchtbericht (2008). http://www.bmg.bund.de
5. Kintz P (2002) A new series of 13 buprenorphine-related deaths. Clin Biochem 35:513-516
6. Bomsien S, Aderjan R, Mattern R, Skopp G (2006) Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes. Eur J Clin Pharmacol 62:639-643
7. Megarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ (2006) Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 25:79-85
8. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE (1984) The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 12:577-581
9. Chang Y, Moody DE (2009) Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Letters 3:101-107
10. Kintz P (2001) Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 121:65-69
11. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170-171
12. Kitz R, Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249
13. Worm K, Steentoft A, Kringsholm B (1993) Methadone and drug addicts. Int J Legal Med 106:119-123
14. Kaa E, Teige B (1993) Drug-related deaths during the 1980s. A comparative study of drug addict deaths examined at the institutes of forensic medicine in Aarhus, Denmark, and Oslo, Sweden. Int J Legal Med 106:5-9
15. Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G (2000) Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci 45:226-228
16. Boyd J, Randell T, Luurila H, Kuisma M (2003) Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 47:1031-1033
17. Skopp G, Bomsien S, Zimmer G (2008) Buprenorphin und Benzodiazepine - ein potentiell tödlicher Cocktail? J Addiction Res Pract 54:188-189
18. Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833
19. Miners JO, McKinnon RA, Mackenzie PI (2002) Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182:453-456
20. Argikar UA, Iwuchukwu OF, Nagar S (2008) Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. Expert Opin Drug Metab Toxicol 4:879-894
21. Miners JO, Knights KM, Houston JB, Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539
22. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423-459
23. Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132
24. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI (1996) Phenacetin Odeethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacol (Berl) 128:398-407
25. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147
26. Murphy CM, Huestis MA (2005) Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-D-glucuronide and norbuprenorphine-3-beta-D-glucuronide in human plasma. J Mass Spectrom 40:70-74
27. Hara Y, Nakajima M, Miyamoto K, Yokoi T (2007) Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are coadministered with morphine. Drug Metab Pharmacokinet 22:103-112